600285 羚锐制药
2026/09 - 九个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入3,139,9543.24%3,853,3913,500,8313,311,4733,001,862
减:营业总成本2,346,7390.63%3,029,6712,768,1492,683,3042,584,417
    其中:营业成本658,08513.99%769,552846,562884,387832,114
               财务费用(9,741)90.53%(5,090)(18,885)(35,120)(26,588)
               资产减值损失(342)488.08%(608)(502)(2,873)(171)
公允价值变动收益21,5542,591.86%(7,325)(10)1215,926
投资收益33,590-8.54%49,99640,21420,15458,655
    其中:对联营企业和合营企业的投资收益13-108.52%(426)1,824(385)43,350
营业利润840,76010.86%887,274810,302656,307517,121
利润总额839,39510.80%879,466827,573653,044517,035
减:所得税费用116,01011.52%117,018104,98884,92851,730
净利润723,38610.69%762,448722,585568,116465,305
减:非控股权益4,58676.13%2,9453460
股东净利润718,79910.43%759,503722,551568,109465,305

市场价值指针
每股收益 (元) *1.26910.54%1.3401.2871.0120.836
每股派息 (元) *----1.1000.9000.8000.600
每股净资产 (元) *6.0976.45%5.9965.4184.9214.495
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容